顾军,黄敏,吴锦昌,陈杰,朱昕,周俊东,徐颖.超声引导125I粒子植入治疗复发性或转移性浅表恶性肿瘤[J].中国医学影像技术,2010,26(6):1155~1157
超声引导125I粒子植入治疗复发性或转移性浅表恶性肿瘤
Ultrasound-guided 125I radioactive seed implantation in the treatment of recurrent or metastatic superficial malignant tumors
投稿时间:2010-02-15  修订日期:2010-04-20
DOI:
中文关键词:  超声检查  肿瘤  碘放射性同位素
英文关键词:Ultrasonography  Neoplasms  Iodine radioisotopes
基金项目:苏州市科技发展计划(SZD0632)。
作者单位E-mail
顾军 南京医科大学附属苏州医院超声中心,江苏 苏州 215001  
黄敏 南京医科大学附属苏州医院超声中心,江苏 苏州 215001 szhuangmin@163.com 
吴锦昌 南京医科大学附属苏州医院放疗科,江苏 苏州 215001  
陈杰 南京医科大学附属苏州医院放疗科,江苏 苏州 215001  
朱昕 南京医科大学附属苏州医院放疗科,江苏 苏州 215001  
周俊东 南京医科大学附属苏州医院放疗科,江苏 苏州 215001  
徐颖 南京医科大学附属苏州医院超声中心,江苏 苏州 215001  
摘要点击次数: 2970
全文下载次数: 752
中文摘要:
       目的 探讨超声引导下125I粒子植入治疗复发性或转移性浅表恶性肿瘤的方法和疗效。方法 21例复发性或转移性浅表恶性肿瘤患者采用超声实时引导植入125I放射性粒子,术后3个月按WHO恶性肿瘤疗效评价标准进行疗效评价,并对患者进行随访。粒子植入量遵循Halarism 125I经验公式:mCi=Da×5,Da为靶组织长、宽、高之和的平均值(单位为cm)。结果 21例患者125I粒子植入均获得成功。超声能清晰显示肿块,进行准确定位,引导粒子的植入。术后3个月疗效评价:完全缓解12例(57.14%),部分缓解4例(19.05%),稳定3例(14.29%),进展2例(9.52%)。21例患者中位无局部复发生存期7.2个月(6.8~7.6个月)。结论 超声引导125I粒子植入具有微创、准确、安全、有效等优点,对浅表转移及复发恶性肿瘤的治疗具有较高的临床价值。
英文摘要:
      Objective To evaluate the feasibility and effect of ultrasound-guided 125I radioactive seed implantation treatment for recurrent or metastatic superficial malignant tumors. Methods Totally 21 patients with recurrent or metastatic malignant superficial tumors were treated with ultrasound-guided 125I radioactive seeds implantation according to the Halarisms experienced formula (mCi=Da×5), in which Da was the mean sum value of length, width and height of the targeted tissue. The therapeutic effect was evaluated according to WHO tumor assessment criteria 3 months after therapy. Postoperative follow-up was performed as well. Results 125I seeds were successfully implanted into lesions in 21 patients, and the masses were displayed clearly on ultrasonography. Under the guidance of ultrasound, needles were exactly inserted into the masses, and the whole process of implantation was easily observed. Complete remission (CR), partial remission (PR), no change (NC) and progress disease (PD) were seen in 12 (57.14%), 4 (19.05%), 3 (14.29%) and 2 (9.52%) patients, respectively. Median survival time without local recurrence was 7.2 months (6.8—7.6 months). Conclusion Brachytherapy with 125I seeds implantation guided with ultrasound is a safe, minimally invasive and effective treatment with low morbidity for recurrent or metastatic superficial malignant tumors.
查看全文  查看/发表评论  下载PDF阅读器